Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus
Pfefferkorn, J.A., Guzman-Perez, A., Oates, P.J., Litchfield, J., Aspnes, G., Basak, A., Benbow, J., Berliner, M.A., Bian, J., Choi, C., Freeman-Cook, K., Corbett, J.W., Didiuk, M., Dunetz, J.R., Filipski, K.J., Hungerford, W.M., Jones, C.S., Karki, K., Ling, A., Li, J.-C., Patel, L., Perreault, C., Risley, H., Saenz, J., Song, W., Tu, M., Aiello, R., Atkinson, K., Barucci, N., Beebe, D., Bourassa, P., Bourbounais, F., Brodeur, A.M., Burbey, R., Chen, J., D'Aquila, T., Derksen, D.R., Haddish-Berhane, N., Huang, C., Landro, J., Lapworth, A.L., MacDougall, M., Perregaux, D., Pettersen, J., Robertson, A., Tan, B., Treadway, J.L., Liu, S., Qiu, X., Knafels, J., Ammirati, M., Song, X., DaSilva-Jardine, P., Liras, S., Sweet, L., Rolph, T.P.
MEDCHEMCOMM
